Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma
Open Access
- 11 November 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Abstract
Increasing evidence indicates that activation of oncogenic pathways contributes to an unfavourable tumour immune microenvironment (TIME), ultimately resulting in resistance to immunotherapy. Here, we aim to identify a critical oncogenic pathway involved in an antigen-expressing c-MYC-lucOSOE/Tp53KO hepatocellular carcinoma (HCC) mouse model that simulates immune response against tumour-associated antigens. Using data-independent acquisition proteomics, we reveal the role of wild-type KRAS in immune escaped mouse HCC tumours, with EGF concurrently activating EGFR/MEK/ERK signalling. Single cell RNA sequencing data analysis reveals that KRAS signalling intrinsically inhibits interferon-mediated MHC-I expression and extrinsically impairs CD8+ T cell activity due to the suppression of CXCL9 through the EGFR/MEK/ERK pathway. We observe KRAS activation in HCC patients who received immune checkpoint inhibitor (ICI) treatments, where it correlates with poor clinical outcomes. Notably, combination therapy with SOS1 inhibitor MRTX0902, Trametinib, and anti-PD-1 antibody effectively increased intratumoural CD8+ T cell infiltration and improved survival. Our study thus reveals that targeting wild-type KRAS signalling in combination with ICIs may serve as an effective treatment strategy for advanced HCC patients.Keywords
Funding Information
- Research Grants Council, University Grants Committee (RGC TRS T12-705-24-R, C5017-24G)
This publication has 58 references indexed in Scilit:
- KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cellsCancer Cell, 2023
- Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trialJournal of Gastroenterology, 2020
- Ribosome profiling analysis identified a KRAS-interacting microprotein that represses oncogenic signaling in hepatocellular carcinoma cellsScience China Life Sciences, 2019
- KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal CancerCancer Cell, 2019
- Myc Cooperates with Ras by Programming Inflammation and Immune SuppressionCell, 2017
- Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cellsCancer Immunology, Immunotherapy, 2017
- Comprehensive and Integrative Genomic Characterization of Hepatocellular CarcinomaCell, 2017
- KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinomaCancer Immunology, Immunotherapy, 2017
- The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesisJournal of Gastroenterology, 2013
- MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinomaInternational Journal of Cancer, 2003